Regeneron Pharmaceuticals said that European officials recommended granting marketing authorization for its colorectal cancer treatment, Zaltrap. The injectable drug would be used to treat adults. The US Food and Drug Administration approved Zaltrap in August, and marketing authorization applications are under review with other agencies around the world, Regeneron said.